ArticleEJHaem2025
Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dermatologic Toxicities Induced by JAK Inhibitors.American journal of clinical dermatology · 2026Review
- The LNK adaptor protein: a dual regulator of proliferation and migration in solid tumors.Molecular & cellular oncology · 2026Review
- Ruxolitinib-Treated Myeloproliferative Neoplasms: Real-World Infectious Outcomes and Preventive Practices from a Single Center.Mediterranean journal of hematology and infectious diseases · 2026Article
- Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.EJHaem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short-term toxicity profile is well-established, but long-term safety data remains scarce. Methods: We aimed to evaluate toxicity associated with long-term exposure to ruxolitinib (defined as 3 years or longer) through a dual-cohort retrospective study combining a local cohort from Hospital 12 de Octubre with a large real-world dataset from TriNetX database. The selected outcomes were non-melanoma skin cancer (NMSC), other secondary malignancies and infections (zoster, urinary tract infection, pneumonia and sepsis). Results: With a median treatment time of 61.5 months in the local cohort ( Conclusion: Our findings suggest that extended ruxolitinib therapy is associated with specific long-term risks, particularly NMSC and zoster reactivation, while not increasing the incidence of secondary malignancies. These results support continued vigilance and preventive strategies in the setting of long-term ruxolitinib exposure. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.